Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany.
Bone Marrow Transplant. 2011 Oct;46(10):1296-302. doi: 10.1038/bmt.2010.310. Epub 2010 Dec 6.
With the increasing age of patients undergoing allogeneic hematopoietic cell transplantation (HCT), the age of matched related sibling donors (MRDs) is expected to increase. Donor safety and the impact of donors' age on mobilization, collection of peripheral hematopoietic progenitor cells (HPCs), subsequent engraftment and the incidence of GVHD were retrospectively analyzed. A total of 167 patients received HCT from an MRD. Median donors' age was 48 years (67 (40%) donors were ≥50 years including 34 donors ≥60 years). Side effects under mobilization and apheresis were age independent. Grafts from donors <50 years contained more CD34+ cells (median 9 × 10(6)/kg recipient's body weight (RBW)) compared with older donors (median 5.9 × 10(6)/kg RBW) (P<0.0005), whereas harvests from donors ≥60 years contained more natural killer (NK) cells (P=0.003). Engraftment occurred at a median of 12 days after HCT irrespective of donors' age. Increasing age of MRD did not preclude successful mobilization, collection of HPC and engraftment. In the context of more NK cells in grafts from elderly donors, the impact of donors' age on outcome after HCT warrants further studies. Although short-term toxicities of apheresis were not increased with increasing age, long-term donor safety remains an important issue.
随着接受异基因造血细胞移植(HCT)的患者年龄的增加,匹配的相关同胞供者(MRD)的年龄预计也会增加。回顾性分析了供者安全性以及供者年龄对动员、外周造血祖细胞(HPC)采集、随后的植入和移植物抗宿主病(GVHD)发生率的影响。共有 167 例患者接受了来自 MRD 的 HCT。中位供者年龄为 48 岁(67 名(40%)供者年龄≥50 岁,包括 34 名≥60 岁的供者)。动员和单采期间的副作用与年龄无关。年龄<50 岁的供者的移植物中含有更多的 CD34+细胞(中位值为 9×10^6/受者体重(RBW)),与年龄较大的供者(中位值为 5.9×10^6/kg RBW)相比(P<0.0005),而年龄≥60 岁的供者的移植物中含有更多的自然杀伤(NK)细胞(P=0.003)。HCT 后中位植入时间为 12 天,与供者年龄无关。MRD 年龄的增加并不排除成功动员、HPC 采集和植入。在老年供者的移植物中含有更多 NK 细胞的情况下,供者年龄对 HCT 后结果的影响值得进一步研究。尽管随着年龄的增长,单采的短期毒性没有增加,但供者的长期安全性仍然是一个重要问题。